Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

By sjmartinez • October 19, 2023

Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. PMID: 37855026; PMCID: PMC10579289.

Tags: ACTIV-2, covid-19, Infectious Diseases, Inhaled interferon, Publications, Randomized clinical trial, SARS-CoV-2

The association between cannabis use and electrocardiographic abnormalities in people living with HIV

Larson ME, Pan Y, Lakhani F, Chavez J, Santana A, Nogueira NF, Lieberman A, Riley ED, Wu KC, Tien P, Kizer J, Floris-Moore M, Pyslar[...]

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report

Morinishi CD, Brown CE, Younes R. Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A[...]

Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant diarrhea

Livorsi DJ, Merchant J, Cho H, Goetz MB, Alexander B, Goto M. Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant[...]